374 results on '"Verzoni, E."'
Search Results
2. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
Catalog
Books, media, physical & digital resources
3. Does multiparametric (mp) MRI and MRI-informed biopsy improve risk allocation of men at inclusion in active surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial
4. Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years’ experience
5. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial
6. Grade reclassification during active surveillance in low risk prostate cancer men selected with an MRI-informed biopsy
7. 2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
8. Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
9. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
10. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
11. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
12. Targeted treatments in advanced renal cell carcinoma: focus on axitinib
13. 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
14. 1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)
15. LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
16. 1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
17. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy
18. B2 - Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients
19. B11 - Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
20. B10 - Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting
21. B6 - Prospective translational study investigating circulating predictors of outcome to first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC)
22. A0822 - Does multiparametric (mp) MRI and MRI-informed biopsy improve risk allocation of men at inclusion in active surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial
23. A0821 - Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years’ experience
24. COMBINATION IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA
25. 1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment
26. 695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
27. 654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)
28. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101
29. 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic
30. P051 - Grade reclassification during active surveillance in low risk prostate cancer men selected with an MRI-informed biopsy
31. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
32. 1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)
33. 1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
34. 2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
35. Sequential Use of Targeted Therapies (TT) in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience
36. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial
37. 739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)
38. LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
39. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial
40. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases: PO119
41. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): V864
42. Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study
43. Adjuvant treatment of high-risk renal cell carcinoma: The jury is still out
44. Do number of biopsies and PSA doubling time at 3 and 5 years in active surveillance protocols associate with upgrading reclassification?
45. Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out
46. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)
47. Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?
48. Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)
49. Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy
50. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.